Zhuhai Trinomab Pharmaceutical Co (SHSE:688806) Total Operating Expense: ¥601.02 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688806 Zhuhai Trinomab Pharmaceutical Co Ltd SHSE:688806
2 GF Score
Price ¥20.72
! 7 Warning Signs
View Full Analysis

What is Zhuhai Trinomab Pharmaceutical Co Total Operating Expense?

Zhuhai Trinomab Pharmaceutical Co SHSE:688806 -4.38% 2 Total Operating Expense is ¥601.02 Mil as of Dec. 2025. GuruFocus rates SHSE:688806 with a GF Score™ of 2/100. The stock has 7 warning signs investors should review.

Zhuhai Trinomab Pharmaceutical Co's Total Operating Expense for the six months ended in Dec. 2025 was ¥601.02 Mil. Zhuhai Trinomab Pharmaceutical Co's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was ¥601.02 Mil.

Zhuhai Trinomab Pharmaceutical Co Total Operating Expense Related Terms

Zhuhai Trinomab Pharmaceutical Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Zhuhai Trinomab Pharmaceutical Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhuhai Trinomab Pharmaceutical Co Total Operating Expense Chart

Zhuhai Trinomab Pharmaceutical Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
368.97 465.60 509.30 601.02

Zhuhai Trinomab Pharmaceutical Co Semi-Annual Data
Dec22 Dec23 Dec24 Dec25
Total Operating Expense 368.97 465.60 509.30 601.02
SHSE:688806
2GF Score
Zhuhai Trinomab Pharmaceutical Co Ltd SHSE:688806
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhuhai Trinomab Pharmaceutical Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was ¥601.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ¥601.02 Mil mean?
Zhuhai Trinomab Pharmaceutical Co (SHSE:688806) has a Total Operating Expense of ¥601.02 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Zhuhai Trinomab Pharmaceutical Co and its competitors.
Is Zhuhai Trinomab Pharmaceutical Co's Total Operating Expense too high?
Zhuhai Trinomab Pharmaceutical Co's current Total Operating Expense is ¥601.02 Mil. Overall, Zhuhai Trinomab Pharmaceutical Co has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does Zhuhai Trinomab Pharmaceutical Co's Total Operating Expense compare to ZTS?
Zhuhai Trinomab Pharmaceutical Co's Total Operating Expense of ¥601.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Zhuhai Trinomab Pharmaceutical Co and its competitors. Zhuhai Trinomab Pharmaceutical Co's current Total Operating Expense is ¥601.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhuhai Trinomab Pharmaceutical Co stock overvalued right now?
Zhuhai Trinomab Pharmaceutical Co (SHSE:688806) has a current Total Operating Expense of ¥601.02 Mil. The current Total Operating Expense is ¥601.02 Mil. Zhuhai Trinomab Pharmaceutical Co's overall GF Score™ is 2/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Zhuhai Trinomab Pharmaceutical Co (SHSE:688806), the current Total Operating Expense is ¥601.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
2GF Score

Get the complete analysis for SHSE:688806

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥20.72
Price